External broker reports(aggregated public sources), CMB International

CMB International

External broker reports(aggregated public sources)

Incorporated in Hong Kong, supported by the mainland and targeting in global market, CMB International Capital Corporation Limited (“CMBI”) is an integrated financial institution providing comprehensive and professional services. As a wholly-owned subsidiary of China Merchants Bank ("CMB"), by leveraging on the Group’s synergy and coordination in domestic and overseas markets, as well as CMB’s strong resources and outstanding social reputation, CMBI and its subsidiaries have been actively implementing diversified business strategies and set up an overall layout of main business segments including Corporate Finance, Asset Management, Wealth Management, Global Markets and Structured Finance, etc. Adhering to the philosophy of “being clients oriented and increasing our own values by the way of creating value for clients”, CMBI endeavors to provide quality and integrated financial services to institutional, corporate and individual customers both domestic and overseas including Hong Kong IPO sponsorship and underwriting, share placement and rights issue for listed companies, financial advisors, bonds issuance services, asset management, direct investment, wealth management, equity sales and trading, etc.

Equity Bottom-Up

<ul><li>A pioneer biopharma with rich innovative pipelines.</li><li>Akeso has developed a robust pipeline of over 30 drugs, covering oncology, autoimmune and metabolic diseases.</li><li>These pipeline products consist of six bi-specific antibodies, including the two first-in-class BsAb drugs, AK104 (PD-1/CTLA-4) and AK112 (PD-1/VEGF), and other BsAb drug candidates at earlier stage of development, i.e. AK129 (PD1/LAG3) and AK130 (TIGIT/TGF-β fusion protein). </li></ul><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

A pioneer biopharma with rich innovative pipelines.Akeso has developed a robust pipeline of over 30 drugs, covering oncology, autoimmune and metabolic diseases.These pipeline products consist of six bi-specific antibodies, including the two first-in-class BsAb drugs, AK104 (PD-1/CTLA-4) and AK112 (PD-1/VEGF), and other BsAb drug candidates at earlier stage of development, i.e. AK129 (PD1/LAG3) and AK130 (TIGIT/TGF-β fusion protein). Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Akeso, Inc. (9926 HK) – A Leading Biopharma in Bi-Specific Antibodies

China

Akeso Inc. operates operatesa s a biotech company. The compnay develops treatments and therapies for various types of diseases. Akeso serves cutomers worldwide

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Akeso Biopharma Inc (9926 HK)

Akeso, Inc. (9926 HK) – A Leading Biopharma in Bi-Specific Antibodies

A pioneer biopharma with rich innovative pipelines. Akeso has developed a robust pipeline of over 30 drugs, covering oncology, autoimmune and...

CMB International

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)